American College of Gastroenterology

Marla Dubinsky, MD, discusses phase 3 SHINE-2 data showing mirikizumab induced clinical remission in 41.3% of children with UC by week 12.

From oral IL-23 blockade in UC to sex-specific FIT thresholds and a swallowable Barrett’s test, these are 7 trials from ACG 2026 clinicians should know.

David Rubin, MD, discusses GALAXI and GRAVITI data showing guselkumab improved non-passable intestinal stenosis in Crohn’s disease through 2 years.

A real-world ACG 2026 study found 23.4% of patients with PBC on elafibranor reached ALP of 120 U/L or lower, versus 14.6% on obeticholic acid.

Ronnie Fass, MD, discusses phase 3 TRIUMpH-NERD data showing tegoprazan increased heartburn-free and regurgitation-free days vs placebo in NERD.

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.

Nicholas Shaheen, MD, MPH, discusses DETECT-ME data showing a capsule-sponge methylation test detected Barrett’s esophagus with 90% sensitivity.

GI health care use still fell among patients who had already tried another IBS-C drug, per a real world ACG 2026 analysis.

A real world analysis of 470 patients presented at ACG 2026 found median GI visits fell from 4.5 to 3.0 in the year after initiation

Aasma Shaukat, MD, MPH, discusses an updated SimpleScreen CRC blood test with 18.2% sensitivity for advanced precancerous lesions, up from 13.7%.

Evan Dellon, MD, discusses phase 3 CROSSING data in which tezepelumab improved histology, dysphagia, and endoscopic findings vs placebo in EoE.

In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.

Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

In an EPICS-III subgroup analysis, Raj Vuppalanchi, MD, explains why saroglitazar’s larger US treatment effect may reflect differences in disease biology.

Ayah Matar, MD, discusses findings showing elevated serum 7αC4 in SIBO-positive patients, suggesting overlap between SIBO and bile acid diarrhea.

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.

A randomized trial at 5 Brooklyn FQHCs found mailed FIT kits and navigation raised 6-month screening completion to 35.9% vs 23.6% with usual care.

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.

Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

Late-breaking ACG 2025 data link rimegepant to increased rectal compliance and reduced rectal sensation in IBS without constipation.

Phase 2b RELIEVE UCCD results presented at ACG 2025 show duvakitug’s dose-dependent efficacy and favorable safety in Crohn’s disease.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.